Normal pressure hydrocephalus
Conditions
Brief summary
The relative change in gait between walking trials is the primary outcome measure. Walking is examined as the sum of time and steps required to walk a distance of 10 meters, timed up-and-go (TUG), and walking backwards for 3 meters
Detailed description
Quality of life assessed by the EQ-5D-5L self-completion questionnaire and questionnaires 1-2 that estimate the patient's own experience of symptoms and side effects, respectively, The volume of periventricular white matter calculated by volumetric analysis of brain MRI, The total symptomatic change in motor skills, cognition, and continence, assessed using the Swedish iNPH scale, Blood and cerebrospinal fluid biomarkers (neurofilament light chain protein (NFL), amyloid-beta-42, Tau, and glial fibrillary acidic protein (GFAp))
Interventions
DRUGThe Placebo is a Size 00el capsule shell with a Microcrystalline Cellulose fill. Please see Simplified IMPD for detailed information.
DRUGACETAZOLAMIDE
Sponsors
Region Uppsala
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The relative change in gait between walking trials is the primary outcome measure. Walking is examined as the sum of time and steps required to walk a distance of 10 meters, timed up-and-go (TUG), and walking backwards for 3 meters | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life assessed by the EQ-5D-5L self-completion questionnaire and questionnaires 1-2 that estimate the patient's own experience of symptoms and side effects, respectively, The volume of periventricular white matter calculated by volumetric analysis of brain MRI, The total symptomatic change in motor skills, cognition, and continence, assessed using the Swedish iNPH scale, Blood and cerebrospinal fluid biomarkers (neurofilament light chain protein (NFL), amyloid-beta-42, Tau, and glial fibrillary acidic protein (GFAp)) | — |
Countries
Sweden
Outcome results
None listed